---
title: "Prenatal PFAS Linked to Shorter Gestation and Altered Growth to Age 2"
id: "medrxiv-22-pfas-exposure-during-pregnancy-is-associated-with-shorter-gestational-age-at"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-22-pfas-exposure-during-pregnancy-is-associated-with-shorter-gestational-age-at"
content_type: "clinical_feed_article"
specialty: "Pediatrics"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.10.20.26366022v1?rss=1"
published_at: "2026-10-22T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Prenatal PFAS Linked to Shorter Gestation and Altered Growth to Age 2
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-22-pfas-exposure-during-pregnancy-is-associated-with-shorter-gestational-age-at
- **Specialty:** [Pediatrics](https://medichelpline.com/clinical-feed/pediatrics.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.10.20.26366022v1?rss=1)
- **Published At:** 2026-10-22T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The Glowing prospective cohort measured six maternal first-trimester **PFAS** (PFOS, PFOA, PFBS, PFHxS, PFNA, PFHxA) at ~10–12 weeks' gestation and linked exposures to birth and early-life growth outcomes. - Investigators analyzed 217 complete-case mother–child dyads after excluding five with incomplete PFAS data; they used linear regression, SuperImposition by Translation And Rotation growth curve metrics, and quantile g-computation to test associations. - Higher maternal PFOS and **PFHxS** concentrations were associated with shorter **gestational age** overall (example: PFOS β = −0.198 weeks per doubling, 95% CI −0.368 to −0.028, as reported by the authors). - **PFHxS** was associated with lower birth weight (β = −0.048 kg, 95% CI −0.093 to −0.002) in the cohort; several individual PFAS showed sex-specific birth outcome associations concentrated among male neonates. - Among males, PFOS, **PFHxS**, **PFOA**, and **PFNA** associated with shorter gestation; PFNA also associated with shorter birth length in males, per the study team. - For postnatal growth through age two, **PFBS** associated with reduced weight and **fat-free mass** growth intensity; **PFHxS** associated with smaller length and reduced fat-free mass among females. - The combined six-PFAS mixture model showed no association with outcomes in quantile g-computation analyses, and reported associations were robust to adjustment for maternal albumin and estimated glomerular filtration rate. - The report is a medRxiv preprint (not peer reviewed); data are available upon reasonable request. The source did not report additional methodological details beyond those in the abstract and main methods summary contained in the preprint.
## Clinical Analysis & Structured Key Points
PFAS Exposure During Pregnancy Is Associated with Shorter Gestational Age at Birth and with Growth Trajectories During the First 2 Years of Life | medRxiv Skip to main content PFAS Exposure During Pregnancy Is Associated with Shorter Gestational Age at Birth and with Growth Trajectories During the First 2 Years of Life View ORCID Profile Kyle A. Campbell , Clark R. Sims , Priyadarshni Patel , Lauren A. Havens , View ORCID Profile Andrew J. Morris , Kartik Shankar , Kevin J. Pearson , Aline Andres , View ORCID Profile Todd M. Everson doi: https://doi.org/10.64898/2026.10.20.26366022 Kyle A. Campbell 1 Emory University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Kyle A. Campbell Clark R. Sims 2 Arkansas Children's Nutrition Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Priyadarshni Patel 1 Emory University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Lauren A. Havens 3 Central Arkansas Veterans Affairs Healthcare System; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Andrew J. Morris 3 Central Arkansas Veterans Affairs Healthcare System; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Andrew J. Morris Kartik Shankar 4 USDA Agricultural Research Service; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Kevin J. Pearson 5 University of Kentucky College of Medicine Find this author on Google Scholar Find this author on PubMed Search for this author on this site Aline Andres 2 Arkansas Children's Nutrition Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Todd M. Everson 1 Emory University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Todd M. Everson For correspondence: todd.m.everson{at}emory.edu Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Introduction: Prenatal exposure to per- and polyfluoroalkyl substances (PFAS) may influence birth outcomes and postnatal growth and adiposity, yet prospective evidence is limited. We evaluated sex-specific associations of first trimester maternal PFAS exposure with birth outcomes and children's growth and body composition through age two. Methods: Participants were enrolled in the Glowing prospective cohort study (2010-2014, NCT01131117 ). Levels of six PFAS (PFOS, PFOA, PFBS, PFHxS, PFNA, PFHxA) in maternal serum at 10-12 weeks' gestation were analyzed. Five participants were excluded due to unsuccessful PFAS characterization. We tested associations between PFAS exposure and gestational age, birth weight, birth length, and 11 repeated measures of weight, length, fat mass, and fat-free mass (FFM) during the first two years of life with linear regression, SuperImposition by Translation And Rotation growth curve size and intensity, and quantile g-computation. Results: Among 217 complete-case dyads, higher first trimester PFAS concentrations were associated with shorter gestation (PFOS and PFHxS; e.g., PFOS β = −0.198 weeks per doubling, 95% CI −0.368 to −0.028). PFHxS was associated with lower birth weight (β = −0.048 kg, 95% CI −0.093 to −0.002). Among males only, PFOS, PFHxS, PFOA, and PFNA were associated with shorter gestation and PFNA with shorter birth length. For postnatal growth, PFBS was associated with lower weight and fat-free mass growth intensity. PFHxS was associated with smaller length and fat-free mass among females. The joint six-PFAS mixture was not associated with any outcome. Associations were robust to adjustment for maternal albumin and estimated glomerular filtration rate. Conclusion: In a Central Arkansas birth cohort, first trimester maternal PFAS concentrations, particularly PFHxS, were individually associated with shorter gestation and reduced early growth and fat-free mass accrual, with more sex-specific male associations among birth outcomes and more female associations in longitudinal postnatal growth through age two. Competing Interest Statement The authors have declared no competing interest. Clinical Protocols https://clinicaltrials.gov/study/NCT01131117 Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: All participants provided informed consent prior to any study procedures. The protocol was approved by the Institutional Review Board of the University of Arkansas for Medical Sciences. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability Data are available upon reasonable request contingent on data privacy and access regulations. Funder Information Declared National Institute of Environmental Health Sciences , R01 ES032176 , R01 ES036986 , P30 ES019776 , P30 ES026529 USDA Agricultural Research Service , CRIS 3093-10700-001-000-D Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Back to top Previous Next Posted October 22, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following PFAS Exposure During Pregnancy Is Associated with Shorter Gestational Age at Birth and with Growth Trajectories During the First 2 Years of Life Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share PFAS Exposure During Pregnancy Is Associated with Shorter Gestational Age at Birth and with Growth Trajectories During the First 2 Years of Life Kyle A. Campbell , Clark R. Sims , Priyadarshni Patel , Lauren A. Havens , Andrew J. Morris , Kartik Shankar , Kevin J. Pearson , Aline Andres , Todd M. Everson medRxiv 2026.10.20.26366022; doi: https://doi.org/10.64898/2026.10.20.26366022 Share This Article: Copy Citation Tools PFAS Exposure During Pregnancy Is Associated with Shorter Gestational Age at Birth and with Growth Trajectories During the First 2 Years of Life Kyle A. Campbell , Clark R. Sims , Priyadarshni Patel , Lauren A. Havens , Andrew J. Morris , Kartik Shankar , Kevin J. Pearson , Aline Andres , Todd M. Everson medRxiv 2026.10.20.26366022; doi: https://doi.org/10.64898/2026.10.20.26366022 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (633) Allergy and Immunology (914) Anesthesia (344) Cardiovascular Medicine (4940) Dentistry and Oral Medicine (490) Dermatology (425) Emergency Medicine (670) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1665) Epidemiology (16153) Forensic Medicine (35) Gastroenterology (1235) Genetic and Genomic Medicine (7205) Geriatric Medicine (747) Health Economics (1088) Health Informatics (5220) Health Policy (1454) Health Systems and Quality Improvement (1812) Hematology (597) HIV/AIDS (1370) Infectious Diseases (except HIV/AIDS) (16422) Intensive Care and Critical Care Medicine (1192) Medical Education (690) Medical Ethics (156) Nephrology (739) Neurology (7493) Nursing (375) Nutrition (1114) Obstetrics and Gynecology (1280) Occupational and Environmental Health (1028) Oncology (3708) Ophthalmology (1079) Orthopedics (401) Otolaryngology (462) Pain Medicine (491) Palliative Medicine (142) Pathology (716) Pediatrics (1844) Pharmacology and Therapeutics (748) Primary Care Research (781) Psychiatry and Clinical Psychology (6063) Public and Global Health (9911) Radiology and Imaging (2498) Rehabilitation Medicine and Physical Therapy (1499) Respiratory Medicine (1263) Rheumatology (655) Sexual and Reproductive Health (794) Sports Medicine (593) Surgery (794) Toxicology (109) Transplantation (315) Urology (302)
## Related Clinical Research

- [Longitudinal links between pain and anxiety/depression in young people: systematic review and meta](https://medichelpline.com/clinical-feed/medrxiv-10-temporal-associations-between-pain-and-anxiety-depression-in-young-people-a.md)
- [Human Bocavirus Identified in Stool During Pediatric Acute Gastroenteritis Outbreak in Salvador, B](https://medichelpline.com/clinical-feed/medrxiv-16-detection-of-human-bocavirus-in-stool-samples-collected-during-an-outbreak-of.md)
- [Psychosocial profile in adults with congenital heart disease by documented anxiety disorder history](https://medichelpline.com/clinical-feed/plos-one-21-psychosocial-profile-of-adults-with-congenital-heart-disease-according-to.md)
- [Serum IL-6, IL-10 and IL6/IL10 Genotypes in Bangladeshi Patients with Diabetic Neuropathy](https://medichelpline.com/clinical-feed/plos-one-14-association-of-il-6-and-il-10-serum-levels-with-genetic-variants-in-diabetic.md)
- [AbbVie’s lutikizumab meets Phase 3 endpoint in hidradenitis suppurativa but falls short of market](https://medichelpline.com/clinical-feed/stat-news-1-stat-abbvie-skin-disorder-drug-succeeds-in-late-stage-trial-but-results-miss.md)

## Navigation
- [← Back to Pediatrics Feed](https://medichelpline.com/clinical-feed/pediatrics.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.